Maeva Wendremaire

Dr. Maeva Wendremaire

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
TLTatiana Lopez
Tatiana Lopez
MWMaeva Wendremaire
Maeva Wendremaire
JLJimmy Lagarde
Jimmy Lagarde
ODOriane DUQUET
Oriane DUQUET
LALine Alibert
Line Alibert
FLFrédéric Lirussi
Frédéric Lirussi
Many signaling pathways, molecular and cellular actors which are critical for wound healing have been implicated in cancer metastasis. These two conditions are a complex succession of cellular biological events and accurate regulation of these events is essential. Apart from inflammation, macrophages-released ROS arise as major regulators of these processes. But, whatever the pathology concerned, oxidative stress is a complicated phenomenon to control and requires a finely tuned balance over the different stages and responding cells. This review provides an overview of the pivotal role of oxidative stress in both wound healing and metastasis, encompassing the contribution of macrophages. Indeed, macrophages are major ROS producers but also appear as their targets since ROS interfere with their differentiation and function. Elucidating ROS functions in wound healing and metastatic spread may allow the development of innovative therapeutic strategies involving redox modulators.

24 March 2015 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
MBMarina Barrichon
Marina Barrichon
THTarik Hadi
Tarik Hadi
MWMaeva Wendremaire
Maeva Wendremaire
CPClémentine Ptasinski
Clémentine Ptasinski
RSRenaud Seigneuric
Renaud Seigneuric
FLFrédéric Lirussi
Frédéric Lirussi
Background and Purpose: Leptin, an adipokine synthesized by the placenta during pregnancy, has been proposed for the management of preterm labour (PTL), as it is able to prevent in vitro uterine contractility and remodelling associated with labour onset. Another common feature of labour onset is the phenotypic switch of myometrial smooth muscle cells from a proliferative to a hypertrophic state. As proliferative effects have been demonstrated for leptin in other tissues, we aimed to investigate its ability to induce myometrial proliferation and thus to maintain uterine quiescence.Experimental Approach: We stimulated human primary myometrial smooth muscle cells with leptin in the presence or absence of receptor antagonists or signalling pathway inhibitors.Key Results: Leptin induced myometrial cell proliferation in a biphasic manner. At 6.25 ng·mL−1, leptin‐induced proliferation was mediated by the leptin receptor and required the early activation of ERK1/2. At a concentration above 25 ng·mL−1, leptin induced direct non‐specific stimulation of the IL‐6 receptor, leading to NF‐κB activation, and exerted anti‐proliferative effects. However, at 50 ng·mL−1, leptin re‐induces proliferation via IL‐6 receptor stimulation that requires STAT3 and delayed ERK1/2 activation.Conclusions and Implications: These data bring new insights into leptin signalling‐induced myometrial proliferation and its interrelationship with the IL‐6/IL‐6 receptor axis. In the light of our previous work, the present study emphasizes the potential value of leptin in the pharmacological management of PTL and it also strengthens the hypothesis that leptin might be a contributory factor in the parturition‐related disorders observed in obese women.

17 December 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
THTarik Hadi
Tarik Hadi
CRChristophe Ramseyer
Christophe Ramseyer
TGThomas GAUTIER
Thomas GAUTIER
PBPierre-Simon Bellaye
Pierre-Simon Bellaye
TLTatiana Lopez
Tatiana Lopez
FLFrédéric Lirussi
Frédéric Lirussi
In this work, we have explored natural unmodified low- and high-density lipoproteins (LDL and HDL, respectively) as selective delivery vectors in colorectal cancer therapy. We show in vitro in cultured cells and in vivo (NanoSPECT/CT) in the CT-26 mice colorectal cancer model that LDLs are mainly taken up by cancer cells, while HDLs are preferentially taken up by macrophages. We loaded LDLs with cisplatin and HDLs with the heat shock protein-70 inhibitor AC1LINNC, turning them into a pair of “Trojan horses” delivering drugs selectively to their target cells as demonstrated in vitro in human colorectal cancer cells and macrophages, and in vivo. Coupling of the drugs to lipoproteins and stability was assessed by mass spectometry and raman spectrometry analysis. Cisplatin vectorized in LDLs led to better tumor growth suppression with strongly reduced adverse effects such as renal or liver toxicity. AC1LINNC vectorized into HDLs induced a strong oxidative burst in macrophages and innate anticancer immune response. Cumulative antitumor effect was observed for both drug-loaded lipoproteins. Altogether, our data show that lipoproteins from patient blood can be used as natural nanocarriers allowing cell-specific targeting, paving the way toward more efficient, safer, and personalized use of chemotherapeutic and immunotherapeutic drugs in cancer.

10 March 2022 in Cells
Verified
Journal Article
Open access
PDF file
MWMaeva Wendremaire
Maeva Wendremaire
TLTatiana E. Lopez
Tatiana E. Lopez
MBMarina Barrichon
Marina Barrichon
HZHang Zhang
Hang Zhang
THTarik Hadi
Tarik Hadi
FLFrédéric Lirussi
Frédéric Lirussi
Maternal obesity is associated with a wide spectrum of labour disorders, including preterm birth. Leptin, a pro-inflammatory adipokine and a key factor of obesity, is suspected to play a major role in these disorders. OB-R, its receptor, is expressed on macrophages and myocytes, two cell types critical for labour onset. Macrophages secrete reactive oxygen species/pro-inflammatory cytokines, responsible for myometrial differentiation while myocytes control uterine contractions. In this study, we assessed the effect of leptin on myometrial contraction and differentiation using our validated co-culture model of human primary macrophages and myocytes. We demonstrated that leptin had a different effect on myocytes and macrophages depending on the dose. A low leptin concentration induced a tocolytic effect by preventing myocytes’ contraction, differentiation, and macrophage-induced ROS production. Additionally, leptin led to an increase in HLA-G expression, suggesting that the tocolytic effect of leptin may be driven by HLA-G, a tolerogenic molecule. Finally, we observed that recombinant HLA-G also prevented LPS-induced ROS production by macrophages. Altogether, these data provide a putative molecular mechanism by which leptin may induce immune tolerance and therefore interfere with labour-associated mechanisms. Therefore, HLA-G represents a potential innovative therapeutic target in the pharmacological management of preterm labour.

23 September 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
TLTatiana Lopez
Tatiana Lopez
MWMaeva Wendremaire
Maeva Wendremaire
JLJimmy Lagarde
Jimmy Lagarde
ODOriane DUQUET
Oriane DUQUET
LALine Alibert
Line Alibert
FLFrédéric Lirussi
Frédéric Lirussi
Many signaling pathways, molecular and cellular actors which are critical for wound healing have been implicated in cancer metastasis. These two conditions are a complex succession of cellular biological events and accurate regulation of these events is essential. Apart from inflammation, macrophages-released ROS arise as major regulators of these processes. But, whatever the pathology concerned, oxidative stress is a complicated phenomenon to control and requires a finely tuned balance over the different stages and responding cells. This review provides an overview of the pivotal role of oxidative stress in both wound healing and metastasis, encompassing the contribution of macrophages. Indeed, macrophages are major ROS producers but also appear as their targets since ROS interfere with their differentiation and function. Elucidating ROS functions in wound healing and metastatic spread may allow the development of innovative therapeutic strategies involving redox modulators.

3 December 2024 in American Journal of Reproductive Immunology
Verified
Journal Article
Open access
MWMaeva Wendremaire
Maeva Wendremaire
THTarik Hadi
Tarik Hadi
TLTatiana E. Lopez
Tatiana E. Lopez
JGJulien Guy
Julien Guy
FNFabrice Neiers
Fabrice Neiers
FLFrédéric Lirussi
Frédéric Lirussi
Problem: Preterm birth (PTB) remains the leading cause of neonatal morbidity and mortality. Identifying women at high risk of spontaneous preterm labor (PTL) is challenging due to limited efficient diagnostic markers. Since human parturition involves inflammatory immune processes, we hypothesized that phenotyping of maternal peripheral lymphocytes might predict PTL. Therefore, we aimed to explore the relationship between maternal lymphocyte subpopulations and labor onset characterized by delivery within 7 days of admission in women hospitalized for PTL between 24 and 34 weeks of gestation. Methods of Study: Lymphocyte subpopulations were obtained from peripheral blood samples and characterized by flow cytometry: activated and regulatory T cells, natural killer and B cells, and T H 1/T H 2/T H 17 lymphocytes. Data analysis was conducted retrospectively based on the delivery within 7 days of admission. Results: Among 167 women admitted for PTL, less than 10% delivered within 7 days post‐admission. HLA‐DR expression was significantly increased on CD4 + CD8 − , CD4 − CD8 + , and CD4 + CD8 + lymphocytes in women who delivered within 7 days. Subset levels below 5% of CD4 + CD8 − HLA‐DR + lymphocytes and 20% of CD4 + CD8 + HLA‐DR + lymphocytes were associated with no probability of delivering within 7 days. Conclusion: Our study suggests that combining these two consecutive markers allowed us to identify 57% of women hospitalized for PTL with no probability of delivering within 7 days while retaining patients who delivered within 7 days. If prospectively validated, these markers may be able to identify patients at high risk of PTB and avoid a significant number of unnecessary admissions and healthcare costs. Trial Registration: ANSM number: 2010‐A00516‐33; ClinicalTrials.gov identifier: NCT01340222